This constitutes a reasonable background for the exploration of pivotal players within the local immune milieu, such as IL-37, that could be manipulated against tumor growth, similarly to other components of the BLCA TME, e.g., the fibroblast growth factor receptor 3 (FGFR3), that have very recently been suggested as possible therapeutic targets [33]. The gene discussed is IL37; the disease is bladder transitional cell carcinoma.